Volume 24, Number 9—September 2018
Synopsis
Distinguishing Japanese Spotted Fever and Scrub Typhus, Central Japan, 2004– 2015
Table 3
Characteristic |
JSF,
no. (%), n = 31 |
ST,
no. (%), n = 188 |
Non-R, no. (%), n = 97 |
||||||||
JSF vs. non-R† |
ST vs. non-R† |
JSF vs. ST‡ |
|||||||||
OR (95% CI) |
p value |
OR (95% CI) |
p value |
OR (95% CI) |
p value |
||||||
Laboratory data | |||||||||||
Leukocytes >9,800/μL | 5 (16) | 23 (12) | 42 (45) | 0.2 (0.1–0.7) | 0.006 | 0.2 (0.1–0.3) | <0.001 | 1.4 (0.5–3.9) | 0.556 | ||
Hb <11 g/dL (F) or <13.5 g/dL (M) | 5 (16) | 29 (16) | 46 (49) | 0.2 (0.1–0.6) | 0.002 | 0.2 (0.1–0.3) | <0.001 | 1.0 (0.4–2.9) | 0.939 | ||
Platelets <130,000/μL | 22 (71) | 59 (32) | 28 (30) | 5.7 (2.3–13.9) | <0.001 | 1.1 (0.6–1.8) | 0.806 | 5.3 (2.3–12.2) | <0.001 | ||
Albumin <3.4 g/dL | 14 (61) | 37 (29) | 31 (55) | 1.3 (0.5–3.4) | 0.653 | 0.3 (0.2–0.6) | 0.001 | 3.8 (1.5–9.6) | 0.004 | ||
AST >33 IU/L | 29 (94) | 154 (83) | 46 (50) | 14.5 (3.3–64.3) | <0.001 | 4.8 (2.8–8.4) | <0.001 | 3.0 (0.7–13.3) | 0.145 | ||
ALT >42 IU/L | 16 (52) | 100 (54) | 42 (46) | 1.3 (0.6–2.9) | 0.566 | 1.4 (0.8–2.3) | 0.204 | 0.9 (0.4–2.0) | 0.824 | ||
LDH >229 IU/L | 30 (97) | 179 (97) | 70 (78) | 8.6 (1.1–66.8) | 0.040 | 8.5 (3.3–22.1) | <0.001 | 1.0 (0.1–8.7) | 0.996 | ||
Total bilirubin >1.0 mg/dL | 9 (29) | 13 (7) | 15 (17) | 2.0 (0.8–5.1) | 0.166 | 0.4 (0.2–0.8) | 0.016 | 5.2 (2.0–13.6) | 0.001 | ||
Direct bilirubin >0.4 mg/dL | 4 (22) | 7 (5) | 16 (28) | 0.8 (0.2–2.6) | 0.652 | 0.1 (0.1–0.4) | <0.001 | 5.2 (1.3–19.9) | 0.017 | ||
Creatine kinase >150 IU/L | 19 (66) | 46 (29) | 21 (28) | 4.9 (2.0–12.2) | 0.001 | 1.2 (0.6–1.9) | 0.861 | 4.6 (2.0–10.7) | <0.001 | ||
BUN >22 mg/dL | 15 (48) | 35 (19) | 20 (22) | 3.4 (1.4–8.0) | 0.006 | 0.8 (0.5–1.6) | 0.58 | 4.0 (1.8–8.9) | 0.001 | ||
Creatinine >1.2 mg/dL | 11 (35) | 22 (12) | 7 (8) | 6.7 (2.3–19.4) | <0.001 | 1.6 (0.7–4.0) | 0.277 | 4.1 (1.7–9.6) | 0.001 | ||
Sodium <135 mEq/L | 24 (77) | 71 (39) | 16 (17) | 16.3 (6.0–44.3) | <0.001 | 3.0 (1.6–5.6) | <0.001 | 5.4 (2.2–13.2) | <0.001 | ||
Chloride <98 mEq/L | 17 (55) | 37 (22) | 15 (16) | 6.2 (2.5–15.3) | <0.001 | 1.4 (0.7–2.7) | 0.302 | 4.4 (2.0–9.7) | <0.001 | ||
CRP >10 mg/dL | 16 (52) | 32 (18) | 34 (40) | 1.6 (0.7–3.7) | 0.266 | 0.3 (0.2–0.6) | <0.001 | 5.0 (2.2–11.1) | <0.001 | ||
Urine protein | 27 (87) | 116 (75) | 34 (62) | 4.2 (1.3–13.6) | 0.018 | 1.8 (1.0–3.5) | 0.068 | 2.3 (0.7–6.9) | 0.148 | ||
Urine blood |
29 (94) |
122 (79) |
31 (56) |
11.2 (2.4–51.8) |
0.002 |
2.9 (1.5–5.5) |
0.002 |
3.9 (0.9–17.3) |
0.071 |
||
Treatment and prognosis | |||||||||||
Duration of illness§ <5 d | 16 (59) | 74 (39) | 24 (27) | 4.0 (1.6–9.8) | 0.002 | 1.8 (1.0–3.1) | 0.039 | 2.2 (1.0–5.1) | 0.054 | ||
Treatment: MINO/DOXY | 31 (100) | 180 (99) | 42 (91) | Not applicable | 0.144¶ | 17.1 (1.9–157.4) | 0.012 | Not applicable | 1.000¶ | ||
Delayed defervescence# | 11 (37) | 17 (13) | 30 (67) | 0.3 (0.1–0.8) | 0.012 | 0.1 (0–0.2) | <0.001 | 3.8 (1.5–9.3) | 0.004 | ||
Hospitalization | 28 (90) | 104 (55) | 80 (82) | 2.0 (0.5–7.3) | 0.302 | 0.3 (0.1–0.5) | <0.001 | 7.5 (2.2–25.7) | 0.001 | ||
30-d mortality | 0 | 1 (1) | 2 (2) | Not applicable | 1.000§ | 0.3 (0–3.0) | 0.287 | Not applicable | 1.000¶ |
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; BT, body temperature; BUN, blood urea nitrogen; CRP, C-reactive protein; DOXY, doxycycline; F, female patients; Hb, hemoglobin; JSF, Japanese spotted fever; LDH, lactate dehydrogenase; M, male patients; MINO, minocycline; non-R, nonrickettsial diseases; OR, odds ratio; ST, scrub typhus.
†Non-R = reference.
‡ST = reference.
§Duration from the onset of symptoms to the first diagnostic test.
¶Fisher exact tests.
#>3 d to decline of fever <37.3°C.
Page created: August 17, 2018
Page updated: August 17, 2018
Page reviewed: August 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.